IL-10 and IL-10R1 Co-expression Vector for Sustained Anti-inflammatory Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating chronic or neuropathic pain and inflammatory conditions, such as multiple sclerosis and arthritis, face challenges due to dose-dependent down-regulation of IL-10 signaling, which limits the effectiveness of IL-10-mediated suppression of inflammation.
Innovation Solution
Expressing both the IL-10 peptide and its receptor type 1 (IL-10R1) peptide in antigen-presenting cells using vectors like adeno-associated virus or lentivirus, ensuring constitutive autocrine signaling to overcome down-regulation and achieve sustained anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If increasing concentrations of IL-10 are used to enhance anti-inflammatory effects, then the potency of inflammation suppression is improved, but dose-dependent down-regulation of IL-10 signaling occurs which limits effectiveness
Solution Approach 1:
The patent combines IL-10 peptide and IL-10R1 peptide into a single expression vector that co-delivers both components to antigen-presenting cells. This merging allows the system to simultaneously provide the cytokine and its receptor, enabling sustained autocrine signaling without requiring increasing external doses of IL-10, thereby resolving the contradiction between potency and signal sustainability.
Solution Approach 2:
The co-expression of IL-10 and IL-10R1 creates a self-sufficient system where the antigen-presenting cells produce both the signaling molecule and its receptor. This self-service mechanism allows the cells to maintain their own anti-inflammatory signaling independently of external IL-10 supplementation, overcoming the dose-dependent down-regulation problem while maintaining sustained anti-inflammatory effects.
2Productivity
If high doses of IL-10 are administered to overcome down-regulation, then the therapeutic effect is temporarily enhanced, but the therapeutic window is narrowed due to dose-dependent inhibition
Solution Approach 1:
The patent shifts from a single-dose IL-10 approach to a dual-component system (IL-10 + IL-10R1) that operates in a different dimensional space. By co-expressing both peptides from a single vector, the system achieves sustained therapeutic effects through local autocrine signaling rather than relying on escalating external doses, thereby widening the therapeutic window while maintaining productivity.
3Reliability
If IL-10 concentration is increased to maintain signaling efficiency, then the anti-inflammatory response is improved, but receptor down-regulation occurs which reduces signaling efficiency
Solution Approach 1:
The patent employs preliminary action by co-delivering both IL-10 and IL-10R1 peptides before the down-regulation process can occur. The simultaneous presence of the cytokine and its receptor ensures that signaling capacity is maintained from the outset, preventing the progressive loss of signaling efficiency that occurs with sequential or single-component approaches.
Solution Approach 2:
The co-expression system creates a local feedback loop where IL-10 produced by antigen-presenting cells binds to IL-10R1 on the same cells, maintaining autocrine signaling. This feedback mechanism ensures sustained signaling efficiency without requiring increasing external concentrations, thereby resolving the contradiction between reliability and duration.
Data Source
AI summary
This invention relates to methods and compositions for overcoming the dose-dependent down regulation of interleukin 10 (IL-10) by expressing, in addition to an interleukin 10 (IL-10) peptide, an IL-10 receptor type 1 (IL-10R1) peptide. The methods have use in treating a variety of diseases and symptoms, including but not limited to neuropathic or chronic pain; symptoms and physiological damage associated with multiple sclerosis, spinal cord injury, ALS, neuroinflammation, arthritis and other diseases of the joint; and autoimmune diseases.